Exploring the Association between Amyloid-β and Memory Markers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults - 21/11/24
, Y. Gazes 2, C. Habeck 2, Y. Stern 2
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Memory tests vary in their sensitivity for detection of pre-symptomatic Alzheimer’s disease (AD). The Visual Short-Term Memory Binding Test (VSTMBT) identifies AD-related performance deficits in older adults who are otherwise cognitively unimpaired.
Objective |
We investigated the association of this psychometric measure with brain amyloidosis and atrophy.
Design |
Cross-sectional mixed and correlational.
Setting |
Cognitive Reserve Study from Columbia University.
Participants |
a sample of 39 cognitively unimpaired older adults (Age: M=65.3, SD=3.07) was obtained from the above study.
Measurements |
Extensive neuropsychological and neuroimaging (MRI and amyloid-β PET) assessments were carried out.
Results |
Performance on the VSTMBT allowed us to split the sample into Low Binding Cost (LBC, N=21) and High Binding Cost (HBC, N=18). Groups were matched according to age [p=0.702], years of education [0.071], and sex [p=0.291]. HBC’s performance was comparable to that seen in symptomatic AD. Groups only differed in their amyloid-β deposition on PET in regions of the right ventral stream linked to visual cognition and affected early in AD pathogenesis (lateral-occipital cortex, p = 0.008; fusiform gyrus, p = 0.017; and entorhinal cortex, p = 0.046). Other regions known to be linked to low-level visual integration function also revealed increased amyloid-β deposition in HBC.
Conclusions |
VSTMB deficits are associated with neuropathogenesis (i.e., amyloid-β deposition) in the earliest affected regions in pre-symptomatic AD. The VSTMB test holds potential for the identification of cognitively unimpaired older adults with very early AD pathogenesis and may thus be a useful tool for early intervention trials or other forms of clinical research.
Le texte complet de cet article est disponible en PDF.Key words : Visual short-term memory binding, aging, cognitive marker, Alzheimer’s disease, biomarkers
Plan
Vol 11 - N° 2
P. 339-347 - mars 2024 Retour au numéro
Article précédent
- Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project
- K. Malzbender, P. Barbarino, P. Barkman Ferrell, A. Bradshaw, A.J. Brookes, C. Díaz, W.M. van der Flier, J. Georges, O. Hansson, M. Hartmanis, L. Jönsson, R. Krishnan, T. MacLeod, F. Mangialasche, P. Mecocci, C. Minguillon, L. Middleton, S. Pla, S.P. Sardi, M. Schöll, M. Suárez-Calvet, W. Weidner, P.J. Visser, H. Zetterberg, N. Bose, A. Solomon, Miia Kivipelto, AD-RIDDLE Consortium
- Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial
- Felix G. Wittmann, A. Pabst, A. Zülke, M. Luppa, I. Blotenberg, M.I. Cardona, A. Bauer, S. Fuchs, I. Zöllinger, L. Sanftenberg, C. Brettschneider, J. Döhring, L. Lunden, D. Czock, B. Wiese, J.R. Thyrian, W. Hoffmann, T. Frese, J. Gensichen, H.-H. König, H. Kaduszkiewicz, S.G. Riedel-Heller
Bienvenue sur EM-consulte, la référence des professionnels de santé.